ANDA 205057, held by Hikma. Tapentadol Hydrochloride.
As of Nov 16, 2026, ANDA 205057 (Tapentadol Hydrochloride), held by Hikma, was first approved by FDA on Feb 10, 2026, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2026 | Original application | Approved | None posted |
| Tapentadol HydrochlorideEQ 50MG BASE · tablet;oral | Tapentadol Hydrochloride | Discontinued |
| Tapentadol HydrochlorideEQ 75MG BASE · tablet;oral | Tapentadol Hydrochloride | Discontinued |
| Tapentadol HydrochlorideEQ 100MG BASE · tablet;oral | Tapentadol Hydrochloride | Discontinued |
| Jun 18, 2026 | Supplement 3REMS | Approved | None posted |
| Feb 10, 2026 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters